JP2005506087A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005506087A5 JP2005506087A5 JP2003538376A JP2003538376A JP2005506087A5 JP 2005506087 A5 JP2005506087 A5 JP 2005506087A5 JP 2003538376 A JP2003538376 A JP 2003538376A JP 2003538376 A JP2003538376 A JP 2003538376A JP 2005506087 A5 JP2005506087 A5 JP 2005506087A5
- Authority
- JP
- Japan
- Prior art keywords
- dsrna
- strand
- helicase
- medicament
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108060004795 Methyltransferase Proteins 0.000 claims 17
- 239000003814 drug Substances 0.000 claims 17
- 239000002773 nucleotide Substances 0.000 claims 16
- 125000003729 nucleotide group Chemical group 0.000 claims 16
- 230000003612 virological effect Effects 0.000 claims 13
- 238000000034 method Methods 0.000 claims 12
- 241000282472 Canis lupus familiaris Species 0.000 claims 8
- 239000003094 microcapsule Substances 0.000 claims 8
- 239000002088 nanocapsule Substances 0.000 claims 8
- 229920000642 polymer Polymers 0.000 claims 8
- 230000002401 inhibitory effect Effects 0.000 claims 7
- 241000711549 Hepacivirus C Species 0.000 claims 6
- 230000000295 complement effect Effects 0.000 claims 6
- 241001493065 dsRNA viruses Species 0.000 claims 6
- 238000009472 formulation Methods 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 229920002477 rna polymer Polymers 0.000 claims 6
- 108091005804 Peptidases Proteins 0.000 claims 5
- 239000004365 Protease Substances 0.000 claims 5
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 4
- 108010076039 Polyproteins Proteins 0.000 claims 4
- 108020000999 Viral RNA Proteins 0.000 claims 4
- 241000700605 Viruses Species 0.000 claims 4
- 238000002347 injection Methods 0.000 claims 4
- 239000007924 injection Substances 0.000 claims 4
- 239000000693 micelle Substances 0.000 claims 4
- 239000000243 solution Substances 0.000 claims 4
- 208000036142 Viral infection Diseases 0.000 claims 3
- 239000002904 solvent Substances 0.000 claims 3
- 230000009385 viral infection Effects 0.000 claims 3
- 230000037396 body weight Effects 0.000 claims 2
- 238000001802 infusion Methods 0.000 claims 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000010076 replication Effects 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10155280 | 2001-10-26 | ||
| DE10158411 | 2001-11-29 | ||
| DE10160151A DE10160151A1 (de) | 2001-01-09 | 2001-12-07 | Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens |
| PCT/EP2002/000151 WO2002055692A2 (de) | 2001-01-09 | 2002-01-09 | Verfahren zur hemmung der expression eines zielgens und medikament zur therapie einer tumorerkrankung |
| PCT/EP2002/000152 WO2002055693A2 (de) | 2001-01-09 | 2002-01-09 | Verfahren zur hemmung der expression eines zielgens |
| DE10235621 | 2002-08-02 | ||
| PCT/EP2002/011973 WO2003035876A1 (de) | 2001-10-26 | 2002-10-25 | Verwendung einer doppelsträngigen ribonukleinsäure zur behandlung einer infektion mit einem (+)-strang-rna-virus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005506087A JP2005506087A (ja) | 2005-03-03 |
| JP2005506087A5 true JP2005506087A5 (OSRAM) | 2006-01-05 |
Family
ID=34799649
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003538376A Withdrawn JP2005506087A (ja) | 2001-10-26 | 2002-10-25 | プラス鎖rnaウイルスによる感染症を処置するための2本鎖リボ核酸の使用 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US20050119202A1 (OSRAM) |
| JP (1) | JP2005506087A (OSRAM) |
| CN (1) | CN1608133A (OSRAM) |
| WO (1) | WO2003035876A1 (OSRAM) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| DE10100586C1 (de) | 2001-01-09 | 2002-04-11 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines Ziegens |
| US7829693B2 (en) | 1999-11-24 | 2010-11-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
| EP1309726B2 (en) | 2000-03-30 | 2018-10-03 | Whitehead Institute For Biomedical Research | Rna sequence-specific mediators of rna interference |
| US20030114410A1 (en) * | 2000-08-08 | 2003-06-19 | Technion Research And Development Foundation Ltd. | Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis |
| US20040259247A1 (en) | 2000-12-01 | 2004-12-23 | Thomas Tuschl | Rna interference mediating small rna molecules |
| US7423142B2 (en) | 2001-01-09 | 2008-09-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of anti-apoptotic genes |
| US8546143B2 (en) | 2001-01-09 | 2013-10-01 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
| US7767802B2 (en) | 2001-01-09 | 2010-08-03 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of anti-apoptotic genes |
| US20050143333A1 (en) * | 2001-05-18 | 2005-06-30 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA) |
| US20050182007A1 (en) * | 2001-05-18 | 2005-08-18 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA) |
| US7745418B2 (en) | 2001-10-12 | 2010-06-29 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting viral replication |
| DE10163098B4 (de) | 2001-10-12 | 2005-06-02 | Alnylam Europe Ag | Verfahren zur Hemmung der Replikation von Viren |
| DE10202419A1 (de) | 2002-01-22 | 2003-08-07 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines durch eine Chromosomen-Aberration entstandenen Zielgens |
| AU2003261449A1 (en) | 2002-08-07 | 2004-02-25 | Compositions for rna interference and methods of use thereof | |
| US20070021365A1 (en) * | 2005-06-21 | 2007-01-25 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of Lysyl oxidase for treating tumor growth and diagnostics relating thereto |
| US20070225242A1 (en) * | 2005-06-21 | 2007-09-27 | The Board Of Trustees Of The Leland Stanford Junior University | Method and composition for treating and preventing tumor metastasis in vivo |
| FR2898908A1 (fr) | 2006-03-24 | 2007-09-28 | Agronomique Inst Nat Rech | Procede de preparation de cellules aviaires differenciees et genes impliques dans le maintien de la pluripotence |
| EP2185198B1 (en) | 2007-08-02 | 2015-01-14 | Gilead Biologics, Inc. | Lox and l0xl2 inhibitors and uses thereof |
| EP2293800B1 (en) | 2008-06-06 | 2016-10-05 | Quark Pharmaceuticals, Inc. | Compositions and methods for treatment of ear disorders |
| CN102405286A (zh) | 2008-09-22 | 2012-04-04 | 阿克赛医药公司 | 减小大小的自递送RNAi化合物 |
| US9107935B2 (en) | 2009-01-06 | 2015-08-18 | Gilead Biologics, Inc. | Chemotherapeutic methods and compositions |
| CA2753388C (en) | 2009-03-23 | 2016-11-29 | Quark Pharmaceuticals, Inc. | Endo180 antibody to treat cancer and fibrotic disease |
| AU2010283997B2 (en) * | 2009-08-21 | 2015-04-09 | Gilead Biologics, Inc. | Methods and compositions for treatment of pulmonary fibrotic disorders |
| JP2013502228A (ja) * | 2009-08-21 | 2013-01-24 | ギリアド バイオロジクス,インク. | invitroスクリーニングアッセイ |
| US20110044907A1 (en) * | 2009-08-21 | 2011-02-24 | Derek Marshall | In vivo screening assays |
| BR112012008084A2 (pt) * | 2009-08-21 | 2019-09-24 | Gilead Biologics Inc | método terapêuticos e composições. |
| KR20120063488A (ko) * | 2009-08-21 | 2012-06-15 | 길리아드 바이오로직스, 인크. | 리실 옥시다제 및 loxl2로부터의 촉매 도메인 |
| RU2015108348A (ru) | 2010-02-04 | 2015-07-20 | Джилид Байолоджикс, Инк. | Антитела, связывающиеся с лизилоксидазоподобным ферментом-2 (loxl2), и способы их применения |
| CN106074591B (zh) | 2010-03-24 | 2020-01-14 | 菲奥医药公司 | 眼部症候中的rna干扰 |
| US9340786B2 (en) | 2010-03-24 | 2016-05-17 | Rxi Pharmaceuticals Corporation | RNA interference in dermal and fibrotic indications |
| AR083445A1 (es) | 2010-10-14 | 2013-02-27 | Univ Mie | siARN CONTRA LA FIBROSIS |
| EP3599280B1 (en) | 2010-10-22 | 2022-11-02 | OliX Pharmaceuticals, Inc. | Nucleic acid molecules inducing rna interference, and uses thereof |
| CN104755620B (zh) * | 2012-05-22 | 2018-03-02 | 奥利克斯医药有限公司 | 具有细胞内穿透能力的诱导rna干扰的核酸分子及其用途 |
| ES2926985T3 (es) | 2014-05-15 | 2022-10-31 | Insmed Inc | Métodos para tratar infecciones pulmonares micobacterianas no tuberculosas |
| HK1244035A1 (en) | 2014-12-15 | 2018-07-27 | Bonac Corporation | Single-stranded nucleic acid molecule for inhibiting tgf- beta 1 expression |
| KR102727666B1 (ko) | 2015-11-16 | 2024-11-08 | 올릭스 주식회사 | MyD88 또는 TLR3을 타겟팅하는 RNA 복합체를 이용한 연령-관련 황반 변성의 치료 |
| US10519449B2 (en) | 2016-02-02 | 2019-12-31 | Olix Pharmaceuticals, Inc. | Treatment of angiogenesis-associated diseases using RNA complexes that target ANGPT2 and PDGFB |
| KR102825946B1 (ko) | 2016-02-02 | 2025-06-27 | 올릭스 주식회사 | IL4Rα, TRPA1, 또는 F2RL1을 표적화하는 RNA 복합체를 사용한 아토피 피부염 및 천식의 치료 |
| KR102339886B1 (ko) | 2016-04-11 | 2021-12-17 | 올릭스 주식회사 | 연결 조직 성장 인자를 표적화하는 rna 복합체를 사용한 특발성 폐 섬유증의 치료 방법 |
| KR101916652B1 (ko) | 2016-06-29 | 2018-11-08 | 올릭스 주식회사 | 작은 간섭 rna의 rna 간섭효과 증진용 화합물 및 이의 용도 |
| EP3580339A4 (en) | 2017-02-10 | 2020-12-23 | Research & Business Foundation Sungkyunkwan University | LONG DOUBLE STRAND RNA FOR RNA INTERFERENCE |
| EP3773505A4 (en) | 2018-03-30 | 2021-12-22 | Insmed Incorporated | PROCESS FOR THE CONTINUOUS MANUFACTURING OF LIPOSOMAL MEDICINAL PRODUCTS |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6506559B1 (en) * | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| AU4411499A (en) * | 1998-06-05 | 1999-12-20 | Human Genome Sciences, Inc. | Connective tissue growth factor-4 |
| DE19956568A1 (de) * | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| EP1309726B2 (en) * | 2000-03-30 | 2018-10-03 | Whitehead Institute For Biomedical Research | Rna sequence-specific mediators of rna interference |
| US20040259247A1 (en) * | 2000-12-01 | 2004-12-23 | Thomas Tuschl | Rna interference mediating small rna molecules |
-
2002
- 2002-10-25 JP JP2003538376A patent/JP2005506087A/ja not_active Withdrawn
- 2002-10-25 WO PCT/EP2002/011973 patent/WO2003035876A1/de not_active Ceased
- 2002-10-25 US US10/493,686 patent/US20050119202A1/en not_active Abandoned
- 2002-10-25 US US10/493,768 patent/US20040248835A1/en not_active Abandoned
- 2002-10-25 CN CNA02826181XA patent/CN1608133A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005506087A5 (OSRAM) | ||
| JP5513126B2 (ja) | 肝疾患を予防および/または制御するための、キサントフモールまたはイソキサントフモールの活性物質としての使用 | |
| JP2005512976A5 (OSRAM) | ||
| CN111557939A (zh) | 法匹拉韦在治疗冠状病毒感染方面的应用 | |
| CN111991401A (zh) | 一种化合物在治疗SARS-CoV-2感染中的应用 | |
| JP2010530423A (ja) | 免疫活性化剤を用いたウイルス感染の早期介入 | |
| JP2010511039A5 (OSRAM) | ||
| CN116459295B (zh) | 一种肺炎清化方及其应用 | |
| RU2678105C2 (ru) | Применение таурина для профилактики и/или лечения заболеваний, вызванных вирусами рода коронавирусов и/или рода ротавирусов | |
| CN113101283B (zh) | 一种多苯环共轭分子在制备抗病毒药物中的用途及抗病毒药物 | |
| WO2025218456A1 (zh) | 巴洛沙韦钠在治疗克里米亚-刚果出血热病毒感染方面的应用 | |
| CN115397410A (zh) | 用于治疗、预防或限制病毒感染发生的方法和组合物 | |
| Huang et al. | Protection effects of mice liver and lung injury induced by coronavirus infection of Qingfei Paidu decoction involve inhibition of the NLRP3 signaling pathway | |
| CN1179726C (zh) | 柚皮苷在制备支持性治疗非典型性肺炎药物中的应用 | |
| JP2019510731A (ja) | 抗ウイルス薬およびウイルス感染症の治療方法 | |
| CN106562970B (zh) | Gs-9620的用途 | |
| Deanasa et al. | The potential of antisense oligonucleotides (ASO) through inhalation based on gold nanoparticle (AuNP) delivery system in inhibiting SARS-CoV-2 replication and transcription | |
| US20240415953A1 (en) | Oral therapeutic vaccine compositions, methods and treatment of covid | |
| CN110179785B (zh) | 魏特酮在制备治疗或预防手足口病药物中的应用 | |
| JP2005532038A5 (OSRAM) | ||
| CN118490680A (zh) | 瑞香素在制备治疗病毒性肺炎的药物中的应用 | |
| CN120459175A (zh) | 一种兽用防疫药物及其制备方法和应用 | |
| CN112641918A (zh) | 姜粉在制备治疗病毒性感冒的药物中的应用 | |
| CN103006632B (zh) | 化合物Clik148在制备治疗脑血管疾病的药物中的应用 | |
| CN118634243A (zh) | Mir2911在制备抗登革病毒denv的药物中的应用 |